- Q3 2009 service job count up 14.4% yoy to 827 jobs - EBITDA margin expanded to 29.8% from 23.2% one year ago - Cashflow from operating activities increased by 27.7% for Q1-Q3 2009 - Strong balance sheet with equity ratio of 81.5% Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this ...
Total Group revenues down 15.0 percent to EUR 944.5 million. After-tax profit of EUR 30.0 million, 55.8 percent down on year-on-year. Professor Bauer considers economic crisis to have bottomed out and expects stabilization at low levels. Forecast for 2009 reaffirmed: total Group revenues of just under EUR 1.3 billion and after-tax profit around a ...
Charlotte, North Carolina (ots/PRNewswire) - - Approximately US$2.6 Billion in Writedowns From Improvement in Company Credit Spreads - Terminating Government Guarantee Term Sheet Costs US$402 Million - Merrill Lynch Platform Continues to Boost Results - Extends US$183.7 Billion in Credit in the Third Quarter - Tier 1 Capital Ratio Rises to ...
Bristol-Myers Squibb and AstraZeneca
Princeton, New Jersey and London (ots/PRNewswire) - Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA(TM) (saxagliptin) 5 mg per day achieved the primary objective of ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar ...
Residual Risk Reduction Initiative Foundation
Barcelona (ots/PRNewswire) - - Surveys Establish Residual Vascular Risk is Associated With Atherogenic Dyslipidemia Suggesting the Need to Reconsider Approach to Management of Lipids - Residual Risk Reduction initiative (R3i) Foundation Presents Early Findings From Unique Global Investigation Into ...
. Total Group revenues down 5.4 percent to EUR 681.0 million. . After-tax profit down EUR 16.1 million to EUR 21.1 million. . Three-segment strategy and global presence proving to be stabilizing factors. . Forecast for 2009: total Group revenues of EUR 1.3 billion and after-tax profit around a third of the ...
Key Figures . Revenue: EUR 2.1 million in H1 2009, up by 37% (H1 2008: EUR 1.5 million) . EBIT: EUR - 4.8 million in H1 2009, improved by 19% (H1 2008: EUR -5.9 million) . Net loss: EUR - 4.8 million in H1 2009, decreased by 15% (H1 2008: EUR -5.6 illion) . Liquid assets: EUR 12.1 million as of 30/06/2009 (31/12/2008: EUR 12.1 million) Highlights of the First Half 2009 . Significantly improved ...
Cambridge, England (ots/PRNewswire) - - Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects Nearly a third (31%) of all bendamustine-treated patients saw all clinical evidence of their advanced chronic lymphocytic leukaemia (CLL) disappear when used as a first-line ...
Ingelheim, Germany (ots/PRNewswire) - - Data From Phase II Studies Investigating BIBW 2992 (Tovok(TM)) and BIBF 1120 (Vargatef(TM)) in NSCLC Patients Presented at 13th World Conference on Lung Cancer (WCLC) INGELHEIM, Germany, August 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the ...
Basel, Switzerland (ots/PRNewswire) - - Not For US Media - Set to Become First Medicine in EU to Treat Patients Aged Four and Older Suffering From Life-Long Cryopyrin-Associated Periodic Syndrome (CAPS)(1) - Ilaris Targets Interleukin-1 Beta (IL-1 Beta), a key Driver of Inflammation(1,2,3) - Studies ...
Cape Town, South Africa (ots/PRNewswire) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society (IAS) conference in Cape Town, South Africa demonstrated non-inferiority regarding efficacy between Viramune(R) (nevirapine) and ritonavir ...
Rockville, Maryland and London (ots/PRNewswire) - - BENLYSTA (belimumab) met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo in BLISS-52 - - First drug for lupus to reach this advanced stage of clinical development and achieve ...
Charlotte, North Carolina (ots/PRNewswire) - - Strong Pretax, Pre-provision Income of US$16 Billion - Another Good Quarter in Capital Markets and Home Loans - Enhanced Capital Strength, Tier 1 Capital Ratio at 11.93 Percent - Extends More Than US$211 Billion in Credit in the Second Quarter - Adds US$4.7 Billion to Credit Loss Reserves Bank of America Corporation today reported second-quarter ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has become the first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine 13 Valent ...
Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter - U.S Commercial Launch Planned for the Summer of 2009 Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) ...
Amsterdam, The Netherlands (ots/PRNewswire) - - "Study Could Have Major Impact on the Decision-Making Process With Respect to Infertility Treatment" New data from an economic analysis presented today at this year's European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in ...
Ingelheim, Germany (ots/PRNewswire) - - For non-U.S. Healthcare Media Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending the approval of a once daily formulation for ...
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) and HomeATM announced today that the recent Payments Card Industry (PCI) 2.0 certification of HomeATM's Safe-T-PIN(TM) is the result of an efficient collaboration between the two leaders on their markets. HomeATM's Safe-T-PIN, powered ...
Maidenhead, England (ots/PRNewswire) - - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated Improvement in Patients With and Without Peripheral ...
Collegeville, Pennsylvania (ots/PRNewswire) - New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most ...
Bourne End, England (ots/PRNewswire) - - Feature-Rich, Value-Priced Bundle Offers a Complete Card Design and Printing Solution for Small and Medium-Size Organisations Zebra Technologies Europe Limited, a global leader in specialty printing and automatic identification solutions, today announced the launch ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. new product Unterföhring (euro adhoc) - 8 June 2009 - Following successful worldwide sales of the first Season, TV-Loonland and French broadcaster Gulli TV have commissioned a ...
Basel, Switzerland (ots/PRNewswire) - - For ex-US Media Only - Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non-small cell lung cancer (NSCLC) who received Avastin(R) (bevacizumab) ...
Astellas Pharma Europe Limited
Prague (ots/PRNewswire) - - Ointment (Tacrolimus Monohydrate) in a New Twice-Weekly Regimen can Help Prevent Eczema Flares Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. ...
San Jose, California (ots/PRNewswire) - - US$19.99 kit allows developers and potential customers to evaluate the capabilities of CryptoAuthentication for preventing counterfeiting of medical and electronic consumables, maintain authenticity of end-product firmware, and protect sensitive transmitted data. ...
. Total Group revenues up 10.5 percent to EUR 375.3 million . Profit after tax of EUR 11.0 million down EUR 1.4 million against previous year . Orders in hand stable in Construction and Resources segments, down substantially in Equipment segment . Forecast for 2009 reaffirmed: total Group ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Media Only - Boehringer Ingelheim's LUX-Lung Programme Moves Forward With New Studies Revealing the Potential of BIBW 2992 in Personalising Lung Cancer Care - The First Presentation of Data From BIBF 1120 in Ovarian Cancer Boehringer Ingelheim ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. finances/molecular diagnostics Berlin, Germany and Seattle, WA, U.S.A., May 11, 2009 (euro adhoc) - Key Figures . Revenue: EUR 1.24 million in Q1 2009, up by 36% (Q1 2008: EUR 0.92 million) . EBIT: EUR -2.31 million in Q1 2009, ...
Mumbai (ots/PRNewswire) - - Evaluation Based on Completeness of Vision and Ability to Execute Tata Communications, a leading provider of a new world of communications, today announced it has been positioned by industry analyst firm Gartner, Inc. in the Challengers quadrant of its "Magic Quadrant for ...